End­points News turned five years old over the week­end. I want­ed to mark the hap­py oc­ca­sion by ex­tend­ing our deep­est grat­i­tude to End­points’ pre­mi­um sub­scribers while out­lin­ing sev­er­al oth­er ways to sup­port us as we go broad­er and get big­ger this year and be­yond.

Same as any busi­ness, we’ve got to cre­ate val­ue and get paid for de­liv­er­ing it. So if you de­pend on End­points to stay abreast on bio­phar­ma de­vel­op­ments, we de­pend on you too.

The best way to sup­port us is by up­grad­ing to a pre­mi­um sub­scrip­tion. It’s our most im­por­tant source of rev­enue be­cause it ties our ed­i­to­r­i­al in­cen­tives di­rect­ly to read­er ex­pec­ta­tions — fo­cus­ing on qual­i­ty over quan­ti­ty. We work to de­liv­er some­thing worth pay­ing for every day. Not just an­oth­er email clog­ging your in­box.

We have two plans: In­sid­er for in­di­vid­u­als ($225/year) and En­ter­prise for com­pa­nies ($1,000/year). Both of them un­lock the com­plete End­points ex­pe­ri­ence and con­tent li­brary. The En­ter­prise plan is a flat rate that cov­ers all em­ploy­ees, and you don’t need to ne­go­ti­ate rates with us or pick who on your team gets ac­cess. Every­one does. Check out our en­tire pre­mi­um cat­a­log here.

And if you have ques­tions, our cus­tomer ser­vice team is quick to re­spond — you can chat with them here.

This year we launched three new ti­tles. End­points FDA+ and End­points Man­u­fac­tur­ing — spear­head­ed by se­nior ed­i­tor Zachary Bren­nan and man­ag­ing ed­i­tor Kyle Blanken­ship, re­spec­tive­ly — is your one-stop look at the most crit­i­cal de­vel­op­ments in those fields and what they mean for bio­phar­ma. And se­nior ed­i­tor Am­ber Tong is be­hind our new End­points Week­ly, which re­caps the busy week in bio­phar­ma every Sat­ur­day morn­ing. You can add these ti­tles to your sub­scrip­tion by vis­it­ing your Read­er Pro­file, or if you’re new to End­points, via our sign-up page.

If a pre­mi­um sub­scrip­tion isn’t in the cards yet, but you’d still like to sup­port us, please help spread the word and share End­points with your col­lab­o­ra­tors. Noth­ing is bet­ter than re­fer­rals, and it’s where we get most of our new sub­scribers. Just share our URLs and for­ward our email re­ports to your col­leagues. Most End­points cov­er­age is free to read, with no pay­ment re­quired for a ba­sic sub­scrip­tion.

We’ve al­so spent the past five years op­ti­miz­ing our ad­ver­tis­ing prod­ucts. So for mar­ket­ing lead­ers who need to reach ei­ther a large or tar­get­ed au­di­ence in the life sci­ences, we’d love to talk.

End­points is dif­fer­ent in that we in­ten­tion­al­ly keep ad­ver­tis­ing space tight. That helps pop the brand ad­ver­tis­ing cam­paigns on our site. It re­duces spon­sor­ship fa­tigue from the read­ers and in­creas­es con­ver­sions. Our chief rev­enue of­fi­cer Mike Peck has built a sales team where re­la­tion­ships mat­ter most. We’re in­ter­est­ed in get­ting more from clients who see ex­cel­lent re­sults with us, not milk­ing every deal for pen­nies. And End­points’ cus­tomer ser­vice, led by our tal­ent­ed COO Shelly Whit­field, is sec­ond-to-none. Her team works to ex­e­cute cam­paigns for 200+ ad­ver­tis­ing clients, and they do great work.

Af­ter five years in busi­ness, we’ve grown to 32 full-time em­ploy­ees with more on the way. 100,000+ in­dus­try pros get our news di­rect­ly in their in­box dai­ly. Dur­ing the pan­dem­ic, our vir­tu­al events at­tract­ed 32,000 at­ten­dees. And yet, End­points’ mis­sion hasn’t changed since day one: In­form and con­nect the bio­phar­ma world with re­lent­less dai­ly re­port­ing.

To all of our cur­rent pre­mi­um sub­scribers who’ve di­rect­ly fund­ed our growth: Thank you. Get­ting to this mile­stone was im­pos­si­ble with­out your sup­port. To every­one who is con­sid­er­ing get­ting one to­day for them­selves or their com­pa­ny: We’ll work hard to con­tin­ue earn­ing your sup­port every day.

The FDA’s Oncology Center of Excellence has been a bright spot within the agency in terms of speeding new treatments to patients. That flexibility was on full display this morning as FDA released new draft guidance spelling out exactly how oncology drug developers can fulfill both the accelerated and full approval’s requirements with just a single randomized controlled trial.

While Congress recently passed legislation that will allow FDA to require confirmatory trials to be recruiting and ongoing prior to granting an accelerated approval, the agency is now making clear that the initial trial used to win the AA, if designed appropriately, can also serve as the trial for converting the accelerated approval into a full approval.

Digital therapeutics company Better Therapeutics announced on Thursday that it’s cutting 35% of its staff as it awaits FDA clearance for its first product.

The company, which launched eight years ago, is one of a growing group of companies seeking a digital alternative to traditional medicine. The space saw a record $7.5 billion in investments in 2021, according to Chris Dokomajilar at DealForma, with uses spanning ADHD, PTSD and other indications. However, private insurers have been slow to hop on board.